The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203.
 
Kelsey L Corrigan
No Relationships to Disclose
 
Rebecca Paulus
No Relationships to Disclose
 
Ann Klopp
No Relationships to Disclose
 
Lari B. Wenzel
No Relationships to Disclose
 
Anamaria R Yeung
No Relationships to Disclose
 
J Spencer Thompson
No Relationships to Disclose
 
Desiree E. Doncals
Research Funding - PreludeDx; Summa Health System
 
Vijayananda Kundapur
Patents, Royalties, Other Intellectual Property - I hold a US patent for "mini beam collimator for medical linear accelerators" Patent No.: US 10,702,711 B2 Date of Patent: Jul. 7,2020 I also hold a Canadian patent for "mini beam collimator for medical linear accelerators" Patent number 2,989,042. date
 
Nancy H Wiggers
No Relationships to Disclose
 
Dasarahally S. Mohan
Employment - The Permanente Medical Group
 
Sharad A. Ghamande
Consulting or Advisory Role - Seagen
Speakers' Bureau - Eisai; Tesaro/GSK
Research Funding - Abbvie (Inst); Advaxis (Inst); Akeso Biopharma (Inst); Aravive (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Ellipses Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Merck (Inst); Merck Serono (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst)
 
Shannon Neville Westin
Consulting or Advisory Role - AstraZeneca; Bayer; BioAscent; Caris Life Sciences; Clovis Oncology; Curio Science; Eisai; EQRX; Genentech; Gerson Lehrman Group; GlaxoSmithKline; Immunogen; Lilly; Medscape; Merck; Mereo BioPharma; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; OncLive; Roche; Seagen; Targeted Oncology; Vaniam Group; Vincerx Pharma; Zentalis
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Mereo BioPharma (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Roche/Genentech (Inst); Zentalis (Inst)
 
Kara Schnarr
No Relationships to Disclose
 
Michael Haas
No Relationships to Disclose
 
David K. Gaffney
Consulting or Advisory Role - AstraZeneca/MedImmune; Merck
Research Funding - Elekta
 
Steven E. Waggoner
No Relationships to Disclose
 
Pamela Vanderwall
No Relationships to Disclose
 
Noha Jastaniyah
No Relationships to Disclose
 
Stephanie L. Pugh
Research Funding - Millennium (Inst); Pfizer (Inst)
 
Lisa A. Kachnic
Consulting or Advisory Role - New B Innovation
Research Funding - Varian Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate